Frontlight ResearchEarly access
Lung cancer trials in France
270 of 318 trials · From ClinicalTrials.gov and EU CTIS (euclinicaltrials.eu), checked 18 November 2026. Ask the study team whether a trial fits you.
- Phase 1/2Taking peoplePhase 1/2 Trial of S241656 in Selected RAS/MAPK Mutation- Positive Malignancies
- Where
- Dijon, Paris, Rennes, Villejuif
- Age
- 18 years and over
- People
- 623 worldwide
- Run by
- Institut de Recherches Internationales Servier
See details and how to joinNCT05786924 · EU 2025-523474-16-00 - Phase 2Taking peopleA Study of HER3-DXd in Subjects With Locally Advanced or Metastatic Solid Tumors
- Where
- Bordeaux, Dijon, Lille, Lyon, Marseille, Nantes, Toulouse, Vandœuvre-lès-Nancy, Villejuif
- Age
- 18 years and over
- People
- 890 worldwide
- Run by
- Daiichi Sankyo
See details and how to joinNCT06172478 · EU 2023-507641-29-00 - Phase 1/2Taking peopleA Phase 1/2 Study of IAM1363 in HER2 Cancers
- Where
- Dijon, Saint-Herblain, Toulouse
- Age
- 18 years and over
- People
- 463 worldwide
- Run by
- Iambic Therapeutics, Inc
See details and how to joinNCT06253871 · EU 2024-519188-17-00 - Phase 3Taking peoplePembrolizumab With or Without Maintenance Sacituzumab Tirumotecan (Sac-TMT; MK-2870) in Metastatic Squamous Non-small Cell Lung Cancer (NSCLC) [MK-2870-023]
- Where
- Angers, Avignon Cedex 9, La Roche Sur Yon Cedex 9, Marseille, Vantoux
- Age
- 18 years and over
- People
- 851 worldwide
- Run by
- Merck Sharp & Dohme LLC
See details and how to joinNCT06422143 · EU 2023-510128-66-00 - Phase 3Taking peopleA Study of Pembrolizumab (MK-3475) With or Without Intismeran Autogene (V940) in Participants With Non-small Cell Lung Cancer (V940-009/INTerpath-009)
- Where
- Caen, Lille, Lyon, Paris Cedex 13, Saint-Herblain Cedex, Tours, Villejuif
- Age
- 18 years and over
- People
- 680 worldwide
- Run by
- Merck Sharp & Dohme LLC
See details and how to joinNCT06623422 · EU 2023-506327-29-00 - Phase 3Taking peopleA Study of Adagrasib Plus Pembrolizumab Plus Chemotherapy vs. Placebo Plus Pembrolizumab Plus Chemotherapy in Participants With Previously Untreated Non-squamous Non-small Cell Lung Cancer With KRAS G12C Mutation (KRYSTAL-4)
- Where
- Amiens Cedex 1, Angers, Boulogne-Billancourt, Brest, Caen Cedex 5, Clermont-Ferrand, Dijon, Grenoble Cedex 9, Limoges Cedex 1, Marseille, Montpellier Cedex 5, Mulhouse, Paris, Saint-Herblain, Vandoeuvre Les Nancy, Villejuif
- Age
- 18 years and over
- People
- 630 worldwide
- Run by
- Mirati Therapeutics Inc.
See details and how to joinNCT06875310 · EU 2024-515698-85-00 - Phase 2Not yet taking people in FranceA Phase 2 Study of VS-7375 in Patients With KRAS G12D-Mutated Non-Small Cell Lung Cancer
- Where
- Bordeaux, Dijon, Lyon, Paris, Suresnes
- Age
- 18 years and over
- People
- 105 worldwide
- Run by
- Verastem, Inc.
See details and how to joinNCT07659782 · EU 2026-526472-23-00 - Phase 2Not yet taking people in FranceA Study to Investigate the Efficacy and Safety of Dato-DXd-based Combinations in Participants With TROP2 NMR+ NSCLC
- Where
- Marseille, Nice, Paris, Pessac, Villefranche-sur-Saône
- Age
- 18 years and over
- People
- 250 worldwide
- Run by
- AstraZeneca
See details and how to joinNCT07941609 - Phase 1Not yet taking people in FranceLong-Term Follow-Up (LTFU) of Participants Treated with Adoptive Cell Therapies
- Where
- Pessac
- People
- 12 worldwide
- Run by
- USWM Ct LLC
See details and how to join2024-513033-21-00 - Phase 3Not yet taking people in FranceA Study of Ivonescimab Versus Durvalumab Following Concurrent Chemoradiation Therapy in Participants with Unresectable Stage III NSCLC
- Where
- Amiens, Caen Cedex 5, Créteil, Limoges, Montpellier Cedex 5, Paris, Rennes Cedex 9, Villejuif
- Age
- 18 years and over
- People
- 183 worldwide
- Run by
- Summit Therapeutics Inc.
See details and how to join2026-526300-67-00 - Phase 3Taking peopleLUNAR-2: TTFields With Pembrolizumab + Platinum-based Chemotherapy for Metastatic NSCLC
- Where
- Créteil, Limoges, Marseille, Nantes, Paris, Pessac, Pierre-Bénite, Strasbourg
- Age
- 18 years and over
- People
- 734 worldwide
- Run by
- NovoCure GmbH
See details and how to joinNCT06216301 - Phase 3Taking peopleA Study to Evaluate the Benefit of Adding Durvalumab After Chemotherapy, Durvalumab and Surgery in Patients With Early-stage, Operable, Non-small Cell Lung Cancer.
- Where
- Angers, Bordeaux, Le Mans Cedex 9, Lyon, Vantoux
- Age
- 18 years and over
- People
- 290 worldwide
- Run by
- ETOP IBCSG Partners Foundation
See details and how to joinNCT06284317 · EU 2023-508773-82-00 - Phase 2/3Not yet taking people in FranceA Safety and Efficacy Study of EIK1001 in Combination With Pembrolizumab and Chemotherapy in Participants With Stage 4 Non-Small Cell Lung Cancer.
- Where
- Montpellier Cedex 5, Mougins, Paris, Villefranche Sur Saone Cedex, Villejuif
- Age
- 18 years and over
- People
- 750 worldwide
- Run by
- Eikon Therapeutics
See details and how to joinNCT07365319 · EU 2025-525013-23-00 - Phase 3Taking peopleMK-3475A±Calderasib (MK-1084) in Completely Resected Stage IIA-IIIB (N2) KRAS G12Cm NSCLC (MK-1084-013)
- Where
- Amiens, Boulogne-Billancourt, Caen Cedex 5, Créteil, Marseille, Montpellier, Orleans Cedex 2, Pessac, Saint-Herblain, Toulon Cedex 9, Vandoeuvre Les Nancy Cedex
- Age
- 18 years and over
- People
- 400 worldwide
- Run by
- Merck Sharp & Dohme LLC
See details and how to joinNCT07431827 · EU 2024-517337-41-00 - Phase 3Taking peopleA Clinical Trial of Adjuvant Intismeran (V940) With or Without Pembrolizumab Coformulated With Berahyaluronidase Alfa (MK-3475A) in High-Risk Stage I Non-Small Cell Lung Cancer (V940-014)
- Where
- Clermont-Ferrand, Dijon, Paris, Pessac, Rennes, Suresnes, Toulouse, Vandoeuvre Les Nancy
- Age
- 18 years and over
- People
- 876 worldwide
- Run by
- Merck Sharp & Dohme LLC
See details and how to joinNCT07513376 · EU 2025-522643-18-00 - Phase 2Not yet taking people in FranceA trial to learn how well Dato-DXd works and how safe it is with other anticancer drugs in adults with TROP2 NMR-positive non-small cell lung cancer
- Where
- Marseille, Nice, Paris, Pessac, Villefranche Sur Saone Cedex
- Age
- 18 years and over
- People
- 146 worldwide
- Run by
- AstraZeneca AB
See details and how to join2025-524836-21-00 - Phase 3Taking peopleA Study Evaluating Sotorasib Platinum Doublet Combination Versus Pembrolizumab Platinum Doublet Combination as a Front-Line Therapy in Participants With Stage IV or Advanced Stage IIIB/C Nonsquamous Non-Small Cell Lung Cancers (CodeBreaK 202)
- Where
- Bayonne, Besancon Cedex, Boulogne-Billancourt, Brest, Caen Cedex 9, Chambéry, Créteil, La Roche Sur Yon Cedex 9, Le Mans Cedex 9, Lille, Marseille, Montpellier, Nantes Cedex 2, Nice Cedex 2, Nîmes, Orleans Cedex 2, Paris, Paris Cedex 14, Paris Cedex 20, Pessac, Poitiers, Quimper Cedex, Reims Cedex, Rennes, Rouen Cedex, Saint-Grégoire, Saint-Priest-en-Jarez, Strasbourg Cedex, Toulon Cedex 9, Toulouse, Toulouse Cedex 3, Tours Cedex 9, Villefranche sur Saône, Villejuif
- Age
- 18 years to 100 years
- People
- 750 worldwide
- Run by
- Amgen
See details and how to joinNCT05920356 · EU 2022-501863-41-00 - Phase 2/3Taking peopleA Study to Compare the Combination of Navlimetostat (BMS-986504) With Pembrolizumab and Chemotherapy Versus Placebo Plus Pembrolizumab and Chemotherapy in First-line Metastatic Non-small Cell Lung Cancer Participants With Homozygous MTAP Deletion
- Where
- Besancon Cedex, Brest Cedex 2, Caen Cedex 5, Clermont-Ferrand, Créteil, Dijon, Marseille, Montpellier Cedex 5, Nice, Paris, Pessac, Pierre-Bénite, Reims, Rennes, Toulouse, Tours, Vandoeuvre Les Nancy Cedex, Villejuif Cedex
- Age
- 18 years and over
- People
- 590 worldwide
- Run by
- Bristol-Myers Squibb
See details and how to joinNCT07063745 · EU 2025-521511-40-00 - Phase 2Not yet taking people in FranceA Trial Evaluating the Anti-tumor Activity of Antibody-based Therapies in Metastatic Cancer Patients
- Where
- Bordeaux, Lyon, Nice Cedex 2, Paris, Toulouse, Villejuif
- Age
- 18 years and over
- People
- 200
- Run by
- Centre Leon Berard
See details and how to joinNCT07936422 · EU 2025-522058-38-00 - Phase 1Active, not recruitingBeamion LUNG-1: A Study to Test Different Doses of Zongertinib in People With Different Types of Advanced Cancer (Solid Tumours With Changes in the HER2 Gene)
- Where
- Bron, Lyon, Marseille, Paris, Rennes, Villejuif Cedex
- Age
- 18 years and over
- People
- 554 worldwide
- Run by
- Boehringer Ingelheim
See details and how to joinNCT04886804 · EU 2024-511246-39-00 - Phase 1/2Active, not recruitingFirst in Human Study of BAY2927088 in Participants Who Have Advanced Non-small Cell Lung Cancer (NSCLC) With Mutations in the Genes of Epidermal Growth Factor Receptor (EGFR) and/or Human Epidermal Growth Factor Receptor 2 (HER2)
- Where
- Bordeaux, Lyon, Paris, Saint-Herblain, Villejuif
- Age
- 18 years and over
- People
- 430 worldwide
- Run by
- Bayer
See details and how to joinNCT05099172 · EU 2023-503795-24-00 - Phase 3Taking peopleA Study of Calderasib (MK-1084) Plus Pembrolizumab (MK-3475) in Participants With KRAS G12C Mutant Non-small Cell Lung Cancer (NSCLC) With Programmed Cell Death Ligand 1 (PD-L1) Tumor Proportion Score (TPS) ≥50% (MK-1084-004/KANDLELIT-004)
- Where
- Avignon, Boulogne-Billancourt, Clermont Ferrand Cedex1, Dijon, Nice, Nimes Cedex 9, Quimper Cedex, Valenciennes
- Age
- 18 years and over
- People
- 348 worldwide
- Run by
- Merck Sharp & Dohme LLC
See details and how to joinNCT06345729 · EU 2023-507776-42-00 - Phase 3Taking peopleTrial of Therapeutic Cancer Vaccine OSE2101 in Patients With Non-Small Cell Lung Cancer and Secondary Resistance to Immune Checkpoint Inhibitor
- Where
- Avignon, Bayonne, Besançon, Bobigny, Brest, Bron, Cholet, Créteil, La Roche-sur-Yon, La Tronche, Le Mans, Limoges, Lyon, Marseille, Montpellier, Mulhouse, Nancy, Nantes, Paris, Pessac, Poitiers, Rennes, Saint-Herblain, Strasbourg, Toulon, Toulouse, Villejuif
- Age
- 18 years and over
- People
- 363 worldwide
- Run by
- OSE Immunotherapeutics
See details and how to joinNCT06472245 - Phase 3Taking peopleThis is a Study to Learn About How the Combination of the Study Medicines Sigvotatug Vedotin Plus Pembrolizumab Works in People With Non-small Cell Lung Cancer With High Levels of PD-L1.
- Where
- Cholet, Creteil Cedex, Marseille, Montpellier, Nice Cedex 2, Paris, Pessac, Quimper Cedex, Rennes, Saint-Herblain, Saint-Herblain Cedex, Toulon, Toulouse, Villejuif
- Age
- 18 years and over
- People
- 714 worldwide
- Run by
- Pfizer
See details and how to joinNCT06758401 · EU 2024-517968-36-00 - Phase 2/3Not yet taking people in FranceStudy of Izalontamab Brengitecan (BMS-986507) Versus Platinum-based Chemotherapy With or Without Amivantamab for EGFR-mutated Non-small Cell Lung Cancer After Failure of EGFR TKI Therapy (IZABRIGHT-Lung01)
- Where
- Bron, La Tronche, Lille, Marseille, Nantes, Paris, Saint-Herblain, Strasbourg, Toulouse, Villejuif
- Age
- 18 years and over
- People
- 661 worldwide
- Run by
- Bristol-Myers Squibb
See details and how to joinNCT07100080